- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT01942382
A Clinical Pharmacology Study of JNS010 (Paliperidone Palmitate) in Patients With Schizophrenia
10 september 2013 bijgewerkt door: Janssen Pharmaceutical K.K.
Clinical Pharmacology Study of JNS010 (Paliperidone Palmitate) in Subjects With Schizophrenia
The purpose of this study is to evaluate the pharmacokinetics (study of what the body does to a drug) and safety of paliperidone palmitate ranging from 75 to 150 milligram equivalents in repeated doses (4 injections) administered in the deltoid muscle (muscle in the shoulder) or gluteal muscle (group of muscles present in the buttocks) in participants with schizophrenia.
Studie Overzicht
Toestand
Voltooid
Conditie
Interventie / Behandeling
Gedetailleerde beschrijving
This is a multicenter (study conducted at multiple sites), open label (all people know the identity of the intervention), randomized (the study medication is assigned by chance), parallel-group (each group of participants will be treated at the same time) study.
Approximately, 60 participants will be enrolled in the study.
This study will consist of a screening phase (maximum 14 days), an observation phase (92 days), and a follow-up phase (98 days).
Participants will be randomly assigned to treatment group A, B, or C.
During the observation phase, participants will receive injections of paliperidone palmitate of concentration ranging from 75 to 150 milligram equivalents in the deltoid muscle or gluteal muscle as applicable on Days 1, 8, 36, and 64 alternating between sides (left/right).
Safety evaluations will include assessment of adverse events, clinical laboratory tests, electrocardiogram, vital signs, physical examination, injection site reaction, drug-induced extrapyramidal symptoms scale, and visual analog scale which will be evaluated throughout the study.
The total study duration for each participant will be approximately 190 days.
Studietype
Ingrijpend
Inschrijving (Werkelijk)
76
Fase
- Fase 1
Deelname Criteria
Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
20 jaar tot 65 jaar (Volwassen, Oudere volwassene)
Accepteert gezonde vrijwilligers
Nee
Geslachten die in aanmerking komen voor studie
Allemaal
Beschrijving
Inclusion Criteria:- Participants had to have the capability to provide informed consent in writing to participate in the study
- Participants with a diagnosis of schizophrenia in accordance with the diagnostic criteria for Diagnostic and Statistical Manual of Mental Disorders -IV-TR (DSM-IV-TR)
- Participants whose psychiatric symptom is considered stable by the investigator/subinvestigator at the time of giving informed consent
- Participants with a Positive and Negative Syndrome Scale (PANSS) score of less than or equal to 4 (moderate) in the following 9 items at screening: delusion, conceptual disorganization, hallucinatory behavior, excitement, grandiosity, suspiciousness/persecution, hostility, uncooperativeness, poor impulse control
- Participants with an experience of taking a risperidone formulation or a paliperidone formulation by 8 days before the initial day (Day 1) of the study treatment
Exclusion Criteria:- DSM-IV-TR diagnosis other than schizophrenia
- DSM-IV-TR diagnosis of substance-related disorders within 180 days before the date of screening
- At a risk of suicide or other-injurious behavior as considered by the investigator/subinvestigator , and participants with a history of suicide attempts
- Concurrent condition of Parkinson's disease (except for drug-induced extrapyramidal syndrome) - Concurrent condition or history of symptomatic cerebrovascular accident
Studie plan
Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Treatment A
Participants will receive 4 injections of paliperidone palmitate 150 milligram in the deltoid muscle on Days 1, 8, 36, and 64.
|
Participants will receive 4 injections of paliperidone palmitate of concentration ranging from 75 to 150 milligram equivalents in deltoid or gluteal muscle as randomized to treatment group A, B, or C on Days 1, 8, 36, and 64.
Andere namen:
|
|
Experimenteel: Treatment B
Participants will receive 4 injections of paliperidone palmitate 75 milligram in the deltoid muscle on Days 1, 8, 36, and 64.
|
Participants will receive 4 injections of paliperidone palmitate of concentration ranging from 75 to 150 milligram equivalents in deltoid or gluteal muscle as randomized to treatment group A, B, or C on Days 1, 8, 36, and 64.
Andere namen:
|
|
Experimenteel: Treatment C
Participants will receive 4 injections of paliperidone palmitate 75 milligram in the gluteal muscle on Days 1, 8, 36, and 64.
|
Participants will receive 4 injections of paliperidone palmitate of concentration ranging from 75 to 150 milligram equivalents in deltoid or gluteal muscle as randomized to treatment group A, B, or C on Days 1, 8, 36, and 64.
Andere namen:
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Plasma concentration of unchanged drug (Paliperidone palmitate)
Tijdsspanne: Days 1 to 190
|
Days 1 to 190
|
|
|
Plasma concentration of active metabolite (paliperidone)
Tijdsspanne: Days 1 to 190
|
Days 1 to 190
|
|
|
Plasma concentration of enantiomer of paliperidone palmitate (R078543)
Tijdsspanne: Days 1 to 190
|
Days 1 to 190
|
|
|
Plasma concentration of enantiomer paliperidone palmitate (R078544)
Tijdsspanne: Days 1 to 190
|
Days 1 to 190
|
|
|
Maximum Observed Plasma Concentration (Cmax) of paliperidone palmitate
Tijdsspanne: Days 1 to 190
|
The Plasma Concentration (Cmax) is defined as maximum observed analyte concentration.
|
Days 1 to 190
|
|
Time to Reach Maximum Observed Plasma Concentration (Tmax) of paliperidone palmitate
Tijdsspanne: Days 1 to 190
|
The Tmax is defined as actual sampling time to reach maximum observed analyte concentration.
|
Days 1 to 190
|
|
Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of paliperidone palmitate
Tijdsspanne: Days 1 to 190
|
The Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) is a measure of the plasma paliperidone concentration from time zero to end of dosing interval.
It is used to characterize drug absorption.
|
Days 1 to 190
|
|
Number of participants with adverse events
Tijdsspanne: Up to Day 190
|
Up to Day 190
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Change from baseline in Positive and Negative Syndrome Scale for Schizophrenia (PANSS)
Tijdsspanne: Screening, Baseline (Day 1), Days 8, 36, 64, and 92
|
The PANSS is a medical scale that assesses various symptoms of schizophrenia.
The symptoms are rated on a 7-point scale from 1 (absent) to 7 (extreme psychopathology).
The total score is the sum of all 30 PANSS items, with a range of 30 (absent) to 210 (extreme ill).
Higher scores indicate worsening.
|
Screening, Baseline (Day 1), Days 8, 36, 64, and 92
|
|
Change From Baseline in Clinical Global Impression Severity (CGI-S) Scale Score
Tijdsspanne: Screening, Baseline (Day 1), Days 8, 36, 64, and 92
|
The CGI-S rating scale is a 7 point global assessment that measures the clinician's impression of the severity of illness exhibited by a participant.
A rating of 1 is equivalent to "Normal, not at all ill" and a rating of 7 is equivalent to "Among the most extremely ill participants".
Higher scores indicate worsening.
|
Screening, Baseline (Day 1), Days 8, 36, 64, and 92
|
Medewerkers en onderzoekers
Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.
Sponsor
Publicaties en nuttige links
De persoon die verantwoordelijk is voor het invoeren van informatie over het onderzoek stelt deze publicaties vrijwillig ter beschikking. Dit kan gaan over alles wat met het onderzoek te maken heeft.
Studie record data
Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.
Bestudeer belangrijke data
Studie start
1 april 2009
Primaire voltooiing (Werkelijk)
1 maart 2010
Studie voltooiing (Werkelijk)
1 maart 2010
Studieregistratiedata
Eerst ingediend
10 september 2013
Eerst ingediend dat voldeed aan de QC-criteria
10 september 2013
Eerst geplaatst (Schatting)
16 september 2013
Updates van studierecords
Laatste update geplaatst (Schatting)
16 september 2013
Laatste update ingediend die voldeed aan QC-criteria
10 september 2013
Laatst geverifieerd
1 september 2013
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
- Psychische aandoening
- Schizofreniespectrum en andere psychotische stoornissen
- Schizofrenie
- Fysiologische effecten van medicijnen
- Neurotransmitter agenten
- Moleculaire mechanismen van farmacologische werking
- Depressiva van het centrale zenuwstelsel
- Antipsychotica
- Rustgevende agenten
- Psychotrope medicijnen
- Serotonine agenten
- Dopamine-agenten
- Serotonine 5-HT2-receptorantagonisten
- Serotonine-antagonisten
- Dopamine D2-receptorantagonisten
- Dopamine-antagonisten
- Paliperidon Palmitaat
Andere studie-ID-nummers
- CR100413
- PALM-JPN-3 (Andere identificatie: Janssen Pharmaceutical K.K., Japan)
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .